Your browser doesn't support javascript.
loading
Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project.
Dostálek, Lukás; Benesová, Klára; Klát, Jaroslav; Kim, Sarah H; Falconer, Henrik; Kostun, Jan; Dos Reis, Ricardo; Zapardiel, Ignacio; Landoni, Fabio; Ortiz, David Isla; van Lonkhuijzen, Luc R C W; Lopez, Aldo; Odetto, Diego; Borcinová, Martina; Jarkovsky, Jiri; Salehi, Sahar; Nemejcová, Kristýna; Bajsová, Sylva; Park, Kay J; Javurková, Veronika; Abu-Rustum, Nadeem R; Dundr, Pavel; Cibula, David.
Afiliação
  • Dostálek L; Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic.
  • Benesová K; Institute of Biostatistics and Analyses, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Klát J; Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic.
  • Kim SH; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Falconer H; Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Kostun J; Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
  • Dos Reis R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Zapardiel I; Gynecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain.
  • Landoni F; Department of Obstetrics and Gynecology, University of Milano-Bicocca, Department of Obstetrics and Gynecology, Gynaecologic Oncology Surgical Unit, ASST-Monza, San Gerardo Hospital, Monza, Italy.
  • Ortiz DI; Gynecology Oncology Center, National Institute of Cancerology Mexico, Ciudad De Mexico, Mexico.
  • van Lonkhuijzen LRCW; Department of Gynecological Oncology, Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Amsterdam, Netherlands.
  • Lopez A; Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru.
  • Odetto D; Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina.
  • Borcinová M; Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic.
  • Jarkovsky J; Institute of Biostatistics and Analyses, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Salehi S; Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Nemejcová K; Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
  • Bajsová S; Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic.
  • Park KJ; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Javurková V; Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic.
  • Abu-Rustum NR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Dundr P; Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
  • Cibula D; Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic. Electronic address: dc@davidcibula.cz.
Gynecol Oncol ; 168: 151-156, 2023 01.
Article em En | MEDLINE | ID: mdl-36442426
ABSTRACT

BACKGROUND:

In cervical cancer, presence of lymph-node macrometastases (MAC) is a major prognostic factor and an indication for adjuvant treatment. However, since clinical impact of micrometastases (MIC) and isolated tumor-cells (ITC) remains controversial, we sought to identify a cut-off value for the metastasis size not associated with negative prognosis.

METHODS:

We analyzed data from 967 cervical cancer patients (T1a1L1-T2b) registered in the SCCAN (Surveillance in Cervical CANcer) database, who underwent primary surgical treatment, including sentinel lymph-node (SLN) biopsy with pathological ultrastaging. The size of SLN metastasis was considered a continuous variable and multiple testing was performed for cut-off values of 0.01-1.0 mm. Disease-free survival (DFS) was compared between N0 and subgroups of N1 patients defined by cut-off ranges.

RESULTS:

LN metastases were found in 172 (18%) patients, classified as MAC, MIC, and ITC in 79, 54, and 39 patients, respectively. DFS was shorter in patients with MAC (HR 2.20, P = 0.003) and MIC (HR 2.87, P < 0.001), while not differing between MAC/MIC (P = 0.484). DFS in the ITC subgroup was neither different from N0 (P = 0.127) nor from MIC/MAC subgroups (P = 0.449). Cut-off analysis revealed significantly shorter DFS compared to N0 in all subgroups with metastases ≥0.4 mm (HR 2.311, P = 0.04). The significance of metastases <0.4 mm could not be assessed due to limited statistical power (<80%). We did not identify any cut-off for the size of metastasis with significantly better prognosis than the rest of N1 group.

CONCLUSIONS:

In cervical cancer patients, the presence of LN metastases ≥0.4 mm was associated with a significant negative impact on DFS and no cut-off value for the size of metastasis with better prognosis than N1 was found. Traditional metastasis stratification based on size has no clinical implication.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias do Colo do Útero / Linfonodo Sentinela Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias do Colo do Útero / Linfonodo Sentinela Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article